3/13
08:04 pm
tech
Assessing Bio-Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push [Yahoo! Finance]
Neutral
Report
Assessing Bio-Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push [Yahoo! Finance]
3/13
03:18 pm
tech
Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake? [Yahoo! Finance]
Low
Report
Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake? [Yahoo! Finance]
3/11
09:59 am
tech
What Makes Bio-Techne Corporation (TECH) a Good Investment? [Yahoo! Finance]
Low
Report
What Makes Bio-Techne Corporation (TECH) a Good Investment? [Yahoo! Finance]
3/10
11:02 am
tech
Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/6
05:39 pm
tech
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know [Yahoo! Finance]
Low
Report
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know [Yahoo! Finance]
3/6
12:01 am
tech
Exosome Diagnostic and Therapeutics Market to Reach USD 401.70 Million by 2032 Amid Rapid Advances in Liquid Biopsy, Precision Medicine, and Exosome-Based Drug Delivery - Credence Research [Yahoo! Finance]
Medium
Report
Exosome Diagnostic and Therapeutics Market to Reach USD 401.70 Million by 2032 Amid Rapid Advances in Liquid Biopsy, Precision Medicine, and Exosome-Based Drug Delivery - Credence Research [Yahoo! Finance]
3/5
09:52 am
tech
Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales [Yahoo! Finance]
Medium
Report
Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales [Yahoo! Finance]
3/5
08:08 am
tech
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers [Yahoo! Finance]
Medium
Report
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers [Yahoo! Finance]
3/4
06:30 am
tech
3 Reasons to Avoid TECH and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Avoid TECH and 1 Stock to Buy Instead [Yahoo! Finance]
3/3
01:47 pm
tech
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/3
05:20 am
tech
Middle East DNA Synthesis Market Research Report 2026: $7.6 Bn Industry Trends and Forecasts to 2035 - Precision Medicine, Molecular Diagnostics and Biopharma R&D Investments Accelerate Demand [Yahoo! Finance]
Low
Report
Middle East DNA Synthesis Market Research Report 2026: $7.6 Bn Industry Trends and Forecasts to 2035 - Precision Medicine, Molecular Diagnostics and Biopharma R&D Investments Accelerate Demand [Yahoo! Finance]
2/28
03:42 pm
tech
Will Ella CE-IVD Approval in EU Clinical Labs Change Bio-Techne's (TECH) Diagnostic Platform Narrative? [Yahoo! Finance]
Low
Report
Will Ella CE-IVD Approval in EU Clinical Labs Change Bio-Techne's (TECH) Diagnostic Platform Narrative? [Yahoo! Finance]
2/24
02:35 pm
tech
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections [Yahoo! Finance]
Low
Report
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections [Yahoo! Finance]
2/24
07:21 am
tech
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/24
07:00 am
tech
Bio-Techne to Present at Upcoming Investor Conferences
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences
2/21
06:30 pm
tech
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Medium
Report
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
2/16
06:40 am
tech
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories [Yahoo! Finance]
Low
Report
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories [Yahoo! Finance]
2/16
06:30 am
tech
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories
Low
Report
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories
2/11
09:00 am
tech
Bio-Techne Announces Changes to its Leadership Team
Low
Report
Bio-Techne Announces Changes to its Leadership Team
2/11
07:24 am
tech
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
2/6
11:16 am
tech
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Wells Fargo & Company from $70.00 to $76.00. They now have an "overweight" rating on the stock.
Low
Report
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Wells Fargo & Company from $70.00 to $76.00. They now have an "overweight" rating on the stock.
2/5
10:58 am
tech
Bio-Techne (NASDAQ:TECH) was given a new $65.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Bio-Techne (NASDAQ:TECH) was given a new $65.00 price target on by analysts at Stifel Nicolaus.
2/5
10:27 am
tech
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Evercore ISI from $62.00 to $68.00. They now have an "in-line" rating on the stock.
Low
Report
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Evercore ISI from $62.00 to $68.00. They now have an "in-line" rating on the stock.
2/5
10:04 am
tech
Bio-Techne (NASDAQ:TECH) was given a new $70.00 price target on by analysts at Robert W. Baird.
Low
Report
Bio-Techne (NASDAQ:TECH) was given a new $70.00 price target on by analysts at Robert W. Baird.
2/5
08:11 am
tech
Bio-Techne (NASDAQ:TECH) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Bio-Techne (NASDAQ:TECH) had its "buy" rating reaffirmed by analysts at TD Cowen.